Value of SMAD4 in patients with advanced colorectal cancer (aCRC) receiving an oxaliplatin containing first line chemotherapy – a study of the AIO colorectal cancer group (AIO)
A Baraniskin, D Meier, K Schulmann, HT Arkenau, U Graeven, R Poschen, W Schmiegel, A Tannapfel, A Reinacher-Schick · Zeitschrift für Gastroenterologie · 2009 · Heft 09
Bibliografische Angaben
Zusammenfassung
Introduction: The tumor suppressor SMAD4 is implicated in the development and progression of colorectal cancer (CRC). Its role as a prognostic marker in patients with CRC is poorly defined. We investigated the prognostic value of Smad4 loss in aCRC patients treated with an oxaliplatin containing first line chemotherapy regimen. Methods: Tissue samples were obtained from patients who took part in a randomized phase III chemotherapy trial of the AIO, comparing the use of capecitabine plus oxaliplatin with infusional 5-FU plus oxaliplatin as first-line therapy in aCRC. SMAD4 expression was determined by immunohisto…
